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Abstract
With their location in the perisinusoidal space of Disse, hepatic stellate cells (HSCs) communicate with all of the liver
cell types both by physical association (cell body as well as cytosolic processes penetrating into sinusoids through
the endothelial fenestrations) and by producing several cytokines and chemokines. Bacterial lipopolysaccharide
(LPS), circulating levels of which are elevated in liver diseases and transplantation, stimulates HSCs to produce
increased amounts of cytokines and chemokines. Although recent research provides strong evidence for the role of
HSCs in hepatic inflammation and immune regulation, the number of HSC-elaborated inflammatory and immune
regulatory molecules may be much greater then known at the present time. Here we report time-dependent changes
in the gene expression profile of inflammatory and immune-regulatory molecules in LPS-stimulated rat HSCs, and
their validation by biochemical analyses. LPS strongly up-regulated LPS-response elements (TLR2 and TLR7) but
did not affect TLR4 and down-regulated TLR9. LPS also up-regulated genes in the MAPK, NFκB, STAT, SOCS,
IRAK and interferon signaling pathways, numerous CC and CXC chemokines and IL17F. Interestingly, LPS
modulated genes related to TGFβ and HSC activation in a manner that would limit their activation and fibrogenic
activity. The data indicate that LPS-stimulated HSCs become a major cell type in regulating hepatic inflammatory and
immunological responses by altering expression of numerous relevant genes, and thus play a prominent role in
hepatic pathophysiology including liver diseases and transplantation.
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Introduction
The liver presents the first line of host defense against
pathogens, toxins and aberrant cells by removing them from
the portal circulation. It contains phagocytic Kupffer cells (KCs)
as well as immune competent cells, including antigen-
presenting cells (APCs) [dendritic cells (DCs) and KCs], natural
killer (NK) and NKT cells, and T cells [1-3]. DCs and KCs
activate effector T cells in an antigen-specific and MHC-
restricted manner, which elicit immune response. The liver
exhibits immune tolerance as evident from its harboring of
viruses (HBV and HCV) and infectious organisms (e.g., malaria
parasite), portal venous and oral tolerance to antigens, and
tumor metastasis [4,5], as well as the maintenance of the
allograft function in some liver transplant recipients who
discontinue immunosuppressive drugs, and in many animal
models across the MHC barriers [6-12]. Furthermore, the early
phase of transplantation is characterized by inflammatory and
ischemia/reperfusion-induced liver injury, which is repaired
within a reasonable time period. During exposure to various
pathogens and toxins as well as physical trauma also the liver
is subjected to inflammatory injury that must be resolved in a
timely manner to regain physiologic structure and function.
Recent evidence indicates that the perisinusoidal hepatic
stellate cells (HSCs) play an important role in the regulation of
hepatic inflammation and immunity [13].
HSCs, a major site of retinoid(s) storage and quiescent
physiologically, become activated progressively during liver
injury by releasing retinoids and acquiring a myofibroblast-like
fibrogenic, contractile and proliferative phenotype. Such
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progressive activation of HSCs can be achieved in cell culture
from quiescent [high retinoids and no α-smooth muscle actin
(α-sma) expression] through transitionally activated (moderate
retinoids and α-sma expression) to highly activated (low or no
retinoids and high α-sma expression) [13]. Transitionally
activated HSCs are found in the liver during acute liver injury
and early times after transplantation. We had hypothesized that
interactions of HSCs with the gram-negative bacterial
endotoxin (lipopolysaccharide, LPS), produced in the gut and
delivered to the liver via portal vein almost continuously, might
have significant influence on the hepatic inflammatory and
immune responses. We found that both quiescent [14] and
transitionally activated [15-17] rat HSCs respond to very low
levels of LPS (1 ng/ml), and produce nitric oxide (NO), tumor
necrosis factor α (TNFα) and interleukin 6 (IL6). Mouse HSCs
were also found to produce these and several other cytokines
and chemokines, synthesis of which is influenced by LPS
[18-20].
Both human [21] and murine HSCs [19,20] produce
chemokines that induce chemotaxis of conventional and
regulatory T cells (Tregs) and DCs; also, HSCs’ large stores of
retinoic acid and ability to produce TGFβ can potentially
influence the homing of migratory immune cells [22]. However,
relative to gut DCs, HSCs exhibited much lower potential to
induce CCR9 and α4β7 expression on CD8 T cells, and even
the addition of all-trans retinoic acid failed to increase this
effect [23]. HSCs were shown to present lipid and peptide
antigens to NKT and CD4/CD8 T cells respectively [24], but
they also induce apoptosis of CD4 and CD8 T cells [19,25],
and inhibit splenic DC-induced proliferation of CD8 T cells in a
CD54-dependent manner [26] and CD3/CD28-induced
activation/proliferation of CD8 T cells by expressing B7H4 [27].
In contrast, HSCs promote expansion of Tregs [19,28] that is
augmented when HSCs are pre-treated with LPS [19], enhance
DC- and TGFβ-mediated expansion of Tregs, and block TGFβ-
induced differentiation of T helper 17 (Th17) cells [29].
Interestingly, HSC-modulated Tregs possess greater
immunosuppressive potential than control cells [19], and HSC-
conditioned DCs exhibit reduced potential to activate T cells
[20]. We recently reported decreased LPS-induced hepatic
infiltration of neutrophils in mice depleted of HSCs [30].
Although this information indicates critical role of HSCs in
hepatic inflammation and immune regulation via cell
membrane-associated and soluble factors, the complete
repertoire of the mediators elaborated by LPS-stimulated HSCs
is likely much larger than reported in the literature. To gain
such understanding, which can be useful for future research,
we determined time-dependent changes in inflammatory and
immune-regulatory molecules in LPS-stimulated HSCs.
Materials and Methods
Isolation and culture of stellate cells
The experimental protocols were reviewed and approved by
the Institutional Animal Care and Use Committees of the
University of Pittsburgh (#1108658), University of Cincinnati
(#12-10-16-01) and Veterans Administration at Cincinnati
(12-08-17-02) in accordance with National Institutes of Health
guidelines. HSCs were prepared from the livers of male
Sprague-Dawley rats as described previously [14,17,19]. The
cells were plated at a density of 0.5 x 106 cells/cm2, and the
medium renewed after overnight culture and then on alternate
days. The cells were used on day 7 of culture when the
majority expressed α-sma but contained abundant retinoids as
assessed by immunohistochemistry, vitamin A
autofluorescence and Oil Red staining indicative of
transitionally activated phenotype [20]. The purity was also
determined via flow and Western blot analysis to rule out
contamination of Kupffer cells, endothelial cells and myeloid
cells, as well as via immunohistochemistry for α-sma in
conjunction with vitamin A autofluorescence (Figure S1).
Microarray analysis of HSCs
In two independent experiments, rat HSCs were cultured
with or without 10 ng/ml LPS for 1h and 24h, then harvested for
microarray analysis (i.e., 8 samples). In the first of these
experiments, cells were also harvested after 3h, 6h and 12h of
LPS treatment, for a total of 11 samples. Total RNA was
isolated using the Qiagen RNeasy/Qiashredder systems
(Qiagen Inc., Valencia, CA), and processed and analyzed
using the appropriate Affymetrix products (Affymetrix Inc.,
Santa Clara, CA: cited as catalog numbers in boxed
parentheses). Eukaryote Poly A RNA internal standards
[900433] were added to the samples, and the mRNA
component of the total RNA was reverse-transcribed in the
presence of a T7-(dT)24 primer [900431]. The resulting cDNA
was extracted [900371] and transcribed in the presence of
biotin-labeled ribonucleotides [900449]. 20 μg of the
biotinylated RNA was fragmented [900371] for 35 minutes at
94°C. Each sample was hybridized overnight to a Rat Genome
230 2.0 Array [900506]. These arrays contained >31,000
panels, each targeting a specific transcript sequence.
Approximately 13,400 gene products identified by Entrez Gene
numbers are redundantly targeted by 20,500 panels; the
remaining panels target products have not yet been assigned
Entrez Gene numbers. Affymetrix GCOS 1.4 software was
used to assess the presence or absence of the target
sequence of each panel, and to make pairwise statistical
comparisons among samples. The unscaled mean value was
279 ± 73 (mean ± SD, n = 11), and expression levels were
scaled to 500 using the GCOS default method (2% trimmed
mean). Across all samples, 46.0 ± 3.6% of panels detected
their cognate transcript sequences; 11,379 target sequences
were absent from every sample and were omitted from further
consideration. In both experiments genes were selected if any
LPS-treated time point showed a valid 2-fold change relative to
the 1h control. A valid change required that the GCOS software
called the higher expressing sample Present (i.e., cognate
transcript detected) and that software comparison between the
samples showed a significant increase or decrease. Samples
treated with LPS for 24h were also compared against the 24h
control. Pairwise comparisons of control vs stimulated samples
yielded (2 control x 5 stimulated = 10 comparisons) for the first
experiment and (2 control x 2 stimulated = 4 comparisons) for
the second, a total of 14 pairwise comparisons.
Stellate Cells, Hepatic Inflammation and Immunity
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GCOS generated CEL files and a summary Excel
spreadsheet have been posted in the NCBI GEO database:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=njqfbyueuowsalc&acc=GSE49980
The web-based Ingenuity Pathway Analysis software was
used to assign responsive genes to known canonical
pathways.
Cytokine and nitric oxide measurements
IL6, TNFα, IL1α, IL4, IL13 and RANTES (CCL5) were
measured in HSC culture supernatants with a custom-made rat
Multi-Analyte ELISArray kit (SA Biosciences). The
concentration of nitrite and nitrate (NO end products) was
determined using a colorimetric assay kit (Canyan Chemicals,
Ann Arbor, MI).
Quantitative real time-PCR (qPCR) and Western
analysis
Expression levels of various mRNAs were measured via
qPCR. Briefly, RNAs were prepared from the cells using TRIzol
Reagent (Invitrogen), and cDNAs were prepared using high-
capacity cDNA reverse transcription kit (Applied Biosystems).
qRT-PCR was performed using the Sybr green master mix and
7300 Fast Real-Time PCR System (Applied Biosystems) with
PCR primers listed in Table S1.
For protein (Western) analysis, cell lysates were prepared as
described previously [14,17]. 20 µg of protein was subjected to
SDS–PAGE, and the separated proteins transferred on to an
Immobilon-P membrane (Millipore, Bedford, MA). After blocking
non-specific binding and incubation with appropriate secondary
antibody, detection was achieved using an ECL
chemiluminescence kit (Amersham-Pharmacia). The Abs used
were TLR4 (goat polyclonal: sc12511), MD2 (rabbit polyclonal:
sc-20668) and CD14 (goat polyclonal: sc5749) (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA), Myd88 (rabbit polyclonal)
(Imgenex, San Diego, CA), and α-sma (mouse monoclonal
clone 1A4, A2547) (Sigma, St Louis, MO).
Results and Discussion
Comparison of experiments 1 and 2
Comparison of the T1 and T24 responses between
experiments (Table S2) showed that of the aggregate 2,065
genes responsive at either time in either experiment, 598
responded in both experiments. Of these 567 (95%) were
concordant, responding in the same direction in both
experiments while 31 genes (5%) were discordant, showing
opposite directions of response. Canonical pathways analysis
using IPA software gave the relative enrichment of pathways
(as -log(p) values) for aggregate, concordant, and experiment-
exclusive groups (Tables S3 and S4). Concordance better
identified the 29 pathways in Table S2, where enrichment of
the concordant group exceeded that of the aggregate group.
For the 33 pathways in Table S3, the aggregate group has
greater enrichment, so the pathways may have different
member contributions from the different experiments. Notably,
for very few pathways (7 of 62 total; values in bold in the
Tables S3 and S4) is the enrichment of experiment-exclusive
groups greater than the concordant group, indicating that no
important pathways are exclusive to either of the individual
experiments.
A full survey of concordance was made using contingency
analysis (χ2 test, p < 10 -300); this included genes which
responded in the first experiment at intermediate times (3h, 6h
or 12h) and were also modulated in the second experiment.
(Figure S2). Genes with ≥ 3 of 10 valid 2-fold changes in the
first experiment were more than twice as likely to be modulated
in the second experiment, relative to random chance. This
concordance was so marked that genes with ≥ 7 changes in
the first experiment and ≥ 3 changes in the second were ≥ 9-
fold more common than expected by chance, while genes with
≥ 7 changes in the first experiment and zero changes in the
second appeared ≥ 2-fold less frequently would than expected.
Combining the 7 LPS stimulated samples irrespective of time
permits a nonparametric (Mann-Whitney rank sum) test against
the 4 control samples, with p < 0.042 for control rank sums
which are ≤ 13 or ≥ 35. The 10,903 unique characterized genes
with n (14 ≥ n ≥ 0) valid 2-fold differences (Figure S3, unfilled
bars) were examined for statistical significance. The 1,692
unique characterized genes with changes at p < 0.042 (filled
bars) represent a progressively increasing fraction of the total
changes for a given value of n (filled circles, right hand axis).
Thus for genes that showed n ≥ 9 changes, those changes
were predominantly (fraction > 0.5) statistically significant.
LPS-induced alterations in gene transcripts in HSCs.  In
addition to the time-dependent changes in HSCs due to LPS
stimulation shown Figures 1-9, the magnitude and times of
earliest and maximal changes occurring in the various
transcripts are shown in Table 1 for a quick reference. The
transcripts that are not altered are not shown in this Table.
Expression of LPS response elements by HSCs
The liver is the major target of gut bacteria-derived
pathogen-associated molecular patterns (PAMPs) such as
LPS, peptidoglycans and RNA/DNA. PAMPs are recognized by
the specific toll-like receptors (TLRs): lipoproteins by TLR1 and
TLR2, double stranded (ds)RNA by TLR3, LPS by TLR4,
Flagelin by TLR5, single stranded RNA by TLR7 and TLR8,
and CpG-containing DNA by TLR9. The cell’s response to the
PAMPs is dependent upon the presence and association of
TLRs with their co-receptors and adaptor molecules (e.g.,
CD14, MD2 and MyD88) [31]. LPS elicited variable effects on
the various response elements. LPS increased expression of
Cd14 transcript but not of Myd88 and Md2 (Figure 1A), which
was consistent with their protein expression (Figure 1B). Tlr1,
Tlr2, Tlr4, Tlr7 and Tlr8 all were detected in HSCs (Figure 1A).
LPS did not alter the expression of Tlr1orTlr4 appreciably, but
increased Tlr2 and Tlr7, consistent with the qPCR analysis
(Figure 1C). Western blot analysis also showed no alteration in
TLR4 expression by LPS (Figure 1B). We previously observed
very low mRNA expression of TLR4 in quiescent rat HSCs,
while transitionally activated HSCs showed noticeable TLR4
expression [14]. Quiescent human HSCs were also reported to
express low levels of TLR4 mRNA, which was up-regulated by
activation in culture [32]. In contrast, mouse-derived HSCs
Stellate Cells, Hepatic Inflammation and Immunity
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were reported to express TLR4 at the same level in both
quiescent and activated states [18], and activated human and
mouse HSCs respond to LPS via TLR4 and not TLR2 [18,32].
Brun et al [33] reported that exposing activated murine HSCs to
LPS, LTA or N-acetyl muramyl peptide caused phosphorylation
of ERK1 and subsequent up-regulation and release of TGFβ1,
IL6, and monocyte chemoattractant protein 1 (MCP1, encoded
by Ccl2). In C3H/HeJ mice lacking TLR4, LPS-mediated effects
were attenuated, but not blocked arguing for an additional
TLR4-independent response to LPS. Indeed, we previously
reported LPS responses in quiescent rat HSCs, which have
minimal expression of TLR4 [17].
Figure 1.  TLR and other LPS-response elements in LPS-
stimulated HSCs.  (A) Microarray data show time-dependent
changes in the indicated transcripts. For clarity control gene
expression at 1 and 24h is offset to 0.5h and 24.5h
respectively. (B) A representative Western blot (left pane) and
densitometric analysis (right panel) of the indicated molecules
at 24h following stimulation with 10 ng/ml LPS. (C) qPCR
analysis of the indicated molecules with p values showing
statistical differences. The values (B,C) shown are form 3
separate determinations from different batches of HSCs.
Statistical significance was derived from student’s t-test using
Microsoft-excel program.
doi: 10.1371/journal.pone.0082159.g001
Tlr8 was down-regulated up to 12h with return to the basal
level by 24h. The microarray did not survey Tlr9 but qPCR
demonstrated its presence in HSCs, which was, interestingly,
down-regulated by LPS (Figure 1C). The robust LPS-induced
increase in the transcript for Tlr7 (Figure 1A, 1C) is interesting
in that TLR7 is located in the membranes of the endosomal
compartment and recognizes ssRNA, a common feature of
viral genomes that are internalized by macrophages [34]. As
TLR7 has been postulated to play a significant role in HCV-
induced immune responses [35], our results suggest a direct
role for HSCs in responding to viral infection. In this regard,
HCV RNA has been shown to incorporate into HSCs resulting
in decreased expression of collagen (COL)1A1, COL4A2,
COL5A1 and COL15A1, and increased expression of MMP1,
MMP3 and MMP12 [36]. However, another study observed
significant correlation of TLR7 levels with the grade of necro-
inflammation, and more advanced stages of liver fibrosis [37].
Figure 2.  Gene expression of MAPKs and NFkB signaling
in LPS-stimulated HSCs.  Microarray data show changes in
the indicated transcripts for MAPK related (A) and NFkB-
related genes (B) in HSCs stimulated with 10 ng/ml LPS. For
clarity control gene expression at 1 and 24h is offset to 0.5h
and 24.5h respectively.
doi: 10.1371/journal.pone.0082159.g002
Stellate Cells, Hepatic Inflammation and Immunity
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Thus, it will be important to ascertain the precise role of HSCs
in hepatic immune response related to HCV RNA-TLR7
interactions. Together, these observations suggest differential
responses of HSCs to LPS depending upon the species from
which they are derived and the state of activation.
LPS-induced signaling coupled to cytokine and
chemokine synthesis.  The gene and protein expressions of
the cytokines and chemokines as well as other biological
mediators are regulated directly or via cross-talk between
various intracellular signaling pathways such as NFkB, MAPKs
(mitogen-activated protein kinases), IRAK (IL1 receptor
associated kinase), STAT (signal transducer and activator of
transcription) and SOCS (suppressor of cytokine signaling).
MAPKs.  Surveying 12 of the first tier (Mapk) genes and nine
of their associated / interacting proteins, 7 and 8 respectively
are expressed in at least six of the 11 samples. Transcripts of
Figure 3.  Gene expression of IRAK, STAT and SOCS
signaling in LPS-stimulated HSCs.  Microarray data show
LPS-induced time-dependent changes in the transcripts for
Irak1-3 (A), and Stat1-3, Socs3 and Socs5 (C), and their
mRNA expressions as determined by qPCR at 24h following
stimulation with LPS (B and D). For clarity control gene
expression at 1 and 24h is offset to 0.5h and 24.5h
respectively. The numbers in the histograms (B and D) are the
p values form 3 separate determinations from different batches
of HSCs. Statistical significance was derived from student’s t-
test using Microsoft-excel program.
doi: 10.1371/journal.pone.0082159.g003
interest include Mapk3 (ERK1), Mapk1 (ERK2), Mapk6 (ERK3),
Mapk9 (JNK2) and Mapk14 (p38) (Figure 2A). Of these
components, Mapk14 shows a valid 2-fold decrease (6h), while
Figure 4.  Changes in interleukins, TNF family members,
iNOS and functionally related genes in LPS-stimulated
HSCs.  (A-C) Microarray data show changes in the indicated
transcripts for interleulins, TNF-related genes and NOS-related
genes. For clarity control gene expression at 1 and 24h is
offset to 0.5h and 24.5h respectively. (D) Release of cytokines
as measured by ELISA and of NO2+NO3 (a measure of NO
synthesis) in the culture supernatants of unstimulated and LPS
(10 ng/ml)-stimulated cells at 24h. The values form 3 separate
determinations from different batches of HSCs. Statistical
significance was derived from student’s t-test using Microsoft-
excel program.
doi: 10.1371/journal.pone.0082159.g004
Stellate Cells, Hepatic Inflammation and Immunity
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Mapk1 expression is decreased to 50.6% of control at the
same time-point. Mapk6 shows a valid increase at 12h, raising
the possibility that increased ERK3 signaling may compensate
for decreases in ERK2 and p38. The second tier (Map2k)
transcripts surveyed are members 1 through 5, of which the
first four are consistently present. Increased expression was
seen for both Map2k1 and Map2k3 (which target ERK1/ERK2
and p38 respectively) while neither Map2k2 nor Map2k4
showed valid changes. If the higher transcript levels result in
higher Map2k activities, these increased activities will give
higher fractional phosphorylation of their respective
(decreased) Mapk targets, repleting the respective Mapk
activities. Of 11 third tier (Map3k) genes surveyed, 8 were
substantially present, of which Map3k1 (encodes MEKK1) and
Map3k4 (encodes MEKK4) showed decreased expression at
Figure 5.  Changes in TGFβ and related genes in LPS-
stimulated HSCs.  (A) Microarray data show LPS-induced
changes in the indicated transcripts in HSCs. For clarity control
gene expression at 1 and 24h is offset to 0.5h and 24.5h
respectively. (B) qPCR data showing mRNA expression of the
indicated molecules at 24h following stimulation with 10 ng/ml
LPS. The numbers are p values form 3 separate
determinations from different batches of HSCs. Statistical
significance was derived from student’s t-test using Microsoft-
excel program.
doi: 10.1371/journal.pone.0082159.g005
6h; MEKK1 activates both Erk1/2 and Jnk2. The strong up-
regulation (max 16 -fold) of Map3k8 (Cot/Tpl2) is interesting as
Tpl2-/- mice are resistant to endotoxic shock, and derived HSCs
show decreased ERK-dependent upregulation of IL1β and
Timp1 in response to LPS [38]. Cot/Tpl2 is activated by IL1,
TNFα and LPS via the IκB kinase-beta (IκBKβ)-catalyzed
phosphorylation of the p105 regulatory subunit [39]. Cot/Tpl2,
which is essential for LPS-induced activation of the MEK/ERK
and JNK kinase pathways, plays an integral role in the
production of pro-inflammatory cytokines such as TNFα and
IL1β in macrophages [40], and of TNFα and IL2 during T
lymphocyte activation [41]. Cot/Tpl2 was also shown to activate
IkB kinases, thus inducing the nuclear translocation of NFkB.
We previously observed inhibition of LPS-induced H2O2, NO,
Figure 6.  Changes in IRF and related genes in LPS-
stimulated HSCs.  (A) Microarray data show LPS-induced in
the indicated transcripts. For clarity control gene expression at
1 and 24h is offset to 0.5h and 24.5h respectively. (B) qPCR
data showing mRNA expression of the indicated molecules at
24h following stimulation with 10 ng/ml LPS. The numbers are
p values form 3 separate determinations from different batches
of HSCs. Statistical significance was derived from student’s t-
test using Microsoft-excel program.
doi: 10.1371/journal.pone.0082159.g006
Stellate Cells, Hepatic Inflammation and Immunity
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TNFα, and IL6 synthesis upon blocking activation of p38-MAPK
and NFkB, but not of ERK1/2- and JNK-MAPK [17]; since the
blockade of p38 MAPK prevented LPS-induced NFkB
activation, the microarray data suggest that Cot/Tpl2 might
regulate NFkB activation in HSCs by inducing p38
phosphorylation initially. However, contrary to this supposition,
Cot/Tpl2 deficiency was shown to increase LPS-induced
Figure 7.  LPS-induced changes in Ccl and Cxcl
chemokines.  Microarray data show LPS-induced changes in
CCL (A) and CXCL (B) class of chemokines in HSCs. For
clarity control gene expression at 1 and 24h is offset to 0.5h
and 24.5h respectively. Inset in (A) shows CCL5 release by
HSCs stimulated with 10 ng/ml LPS for 24h as determined by
ELISA. (C) qPCR data showing mRNA expression of the
indicated molecules at 24h following stimulation with 10 ng/ml
LPS. The numbers are p values form 3 separate
determinations from different batches of HSCs. Statistical
significance was derived from student’s t-test using Microsoft-
excel program.
doi: 10.1371/journal.pone.0082159.g007
activation of p38 and JNK MAPK and expression of iNOS, and
inhibition of PI3K or mTor prevented these regulatory effects of
Cot/Tpl2 [42]. Thus simultaneous activation of both Cot/Tpl2
and p38/NFkB in LPS-stimulated HSCs might indicate counter-
regulatory mechanisms during inflammatory response. In this
regard, anti-inflammatory IL10 which is produced by LPS-
stimulated Kupffer cells has been found to down-regulate
synthesis of TNFα and IL6 by the same cells [43].
All of the five genes in the fourth tier (Map4k) are present
and stable, except Map4k4, which shows a 2-fold increase at
24h. Map4k encodes mitogen-activated protein kinase kinase
kinase kinase 4, an enzyme that activates MAPK8/JNK. In
intact mice, siRNA silencing of Map4k4 expression protects
against LPS lethality by inhibiting production of TNFα and IL1β
[44]. Since LPS-stimulated HSCs produce these mediators,
their contribution to the liver injury via MAP4K4 signaling may
be significant.
NFkB.  The activation and subsequent loss of NFκB protein
from the cytosol [17] is accompanied by substantial increases
Figure 8.  LPS-induced changes in antigen-presenting
molecules.  Microarray data show LPS-induced changes in the
transcripts for indicated antigen-presenting and co-modulatory
molecules (A), and for CD200 and its receptors (B) in HSCs.
For clarity control gene expression at 1 and 24h is offset to
0.5h and 24.5h respectively.
doi: 10.1371/journal.pone.0082159.g008
Stellate Cells, Hepatic Inflammation and Immunity
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82159
Figure 9.  Effect of LPS on the genes associated with HSC activation.  (A, B, D) Microarray data show LPS-induced time-
dependent changes in the indicated transcripts. For clarity control gene expression at 1 and 24h is offset to 0.5h and 24.5h
respectively. Inset in (A) shows a Western blot for α-sma protein expression in unstimulated and LPS (10 ng/ml)-stimulated HSCs.
(C) qPCR data showing mRNA expression of the indicated molecules at 24h following stimulation with 10 ng/ml LPS. The numbers
are p values form 3 separate determinations from different batches of HSCs. Statistical significance was derived from student’s t-
test using Microsoft-excel program.
doi: 10.1371/journal.pone.0082159.g009
Stellate Cells, Hepatic Inflammation and Immunity
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Table 1. Alterations in LPS-induced gene transcripts in HSCs.
 Earliest 2-fold change (h) Max fold increase(Decrease in bold) Time at max change (h)
LPS Response Elements (Figure 1)
Cd14 1 14.0 24
Tlr2 3 9.0 6
Tlr7 1 16.8 6
Tlr8 6 -2.9 6
MAPK Signaling (Figures 2)
Mapk14 6 -2.7 6
Mapk1 6 -2.1 6
Mapk6 12 3.5 12
Map2k1 12 2.6 12
Map2k3 24 3.1 24
Map3k1 6 -3.5 6
Map3k4 6 -3.1 6
Map3k8 1 18 6
Map4k4  (+70%) 24
NFkB Signaling (Figures 3)
Nfkb1 3 7.1 6
Nfkb2 3 8.6 6
Nfkbia 1 23.3 1
Nfkbib 6 3.9 24
Nfkbiz 1 32.8 3
IRAK/STAT/SOCS Signaling (Figures 3)
Irak2 3 6.9 6
Irak3 3 9.5 12
Stat1/Stat4 6 4.0 12
Stat2 3 9 12
Stat3 6 3 6
Socs3 3 6 3
Socs5 3 -2.2 3
Cytokines (Figures 4-6)
Il1a 1 59.7 24
Il1b 1 137.9 12
Il6 3 79 12
Il10 12 242.7 24
Il17f 12 40.2 24
Il17ra  (-48%) 6
Il17re 6 -5.2 24
Tnf 1 419.5 3
Tnfaip6 3 44.8 24
Tgfb1  (+55%) 24
Tgfbr1 3 -7.5 24
Bambi 1 9.8 3
Irf1 3 15.2 3
Irf7 3 30 12
Irf9 3 3.7 12
C-C Chemokines (Figure 7)
Ccl2 1 3.9 24
Ccl3 1 46.2 6
Ccl4 1 52.6 6
Ccl5 3 107.1 12
Ccl6 12 21.5 24
Ccl7 1 18.8 24
Ccl9 1 36.0 6
Ccl19 3 6.1 12
Stellate Cells, Hepatic Inflammation and Immunity
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Table 1 (continued).
 Earliest 2-fold change (h) Max fold increase(Decrease in bold) Time at max change (h)
Ccl20 1 113.7 12
Ccl22 12 3.7 24
CXC Chemokines (Figure 7)
Cxcl1 1 52.3 6
Cxcl2 1 316.8 24
Cxcl3 3 144.8 24
Cxcl5 3 23.2 6
Cxcl9 3 23.8 6
Cxcl11 1 146.2 6
Cxcl13 6 4.3 24
Cxcl16 6 5.0 24
Surface molecules of immune cell interactions (Figure 8)
Cd40 3 186.0 6
Vcam1 1 180.8 3
Cd86 3 9.6 6
RT1-EC2 3 11.6 6
RT1-CE12 6 3.9 24
RT1-T24-3 3 11.7 12
RT1-A2 / RT1-A3 / RT1-EC2 6 4.2 24
RT1-M3-1 6 2.5 12
RT1-N3 6 2.9 6
RT1-S3 3 26.4 12
RT1-DMa 12 -4.4 24
RT1-DMb 12 -4.5 24
Cd200 6 11.0 12
Markers of stellate cell activation (Figure 9)
Acta 1 12 -45.0 24
Acta2 24 -7.6 24
Actg2 24 -25.9 24
Decorin 1 10.9 24
Col1a1 24 -4.4 24
Col3a1 24 -4.0 24
Col1a1 24 -4.4 24
Col4a5 24 -2.9 24
Col5a1 24 -3.9 24
Col8a2 3 4.4 3
Col11a1 3 -110.5 24
Col12a1 24 -4.0 24
Col14a1 12 -4.3 24
Mmp2 3 5.6 24
Mmp3 6 308.1 24
Mmp7 24 -4.1 24
Mmp9 6 230.4 24
Mmp10 6 133.1 24
Mmp13 6 255.4 24
Mmp14 12 2.3 24
Mmp23 24 -3.9 24
doi: 10.1371/journal.pone.0082159.t001
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in the transcripts for NFκB p105 (Nfkb1), NFκB p49/100
(Nfkb2) and IkBα (Nfkbia), and 3.6-fold for IkBβ (Nfkbib)
(Figure 2B). These changes replenish this key signaling
system. While Nfkbia increases most rapidly (at 1h), the other 3
components of the system lag somewhat, increasing between
1 and 3h. Interestingly, the novel zeta (ζ) form of IkB (Nfkbiz)
increases as rapidly as Nfkbia. IkBζ, which is hardly detectable
in resting cells, is strongly induced by LPS or IL1β, but not by
TNFα; localizing in the nucleus, it inhibits NFkB activity [45].
The microarray data thus suggest that the increased IkBζ
expression may be a negative regulator of NFκB-induced pro-
inflammatory and/or other (e.g., activation-related and pro-
fibrogenic) effects of LPS.
IRAK, SOCS and STAT.  The microarray results also
indicate that LPS promotes inflammatory response in HSCs by
instigating cross-talk between IRAK, TLR and NFkB signaling.
While the Irak1 transcript was slightly decreased throughout
the time-course of LPS stimulation of HSCs, Irak2 and Irak3
transcripts increased strongly by 6h (Figure 3A), which was
confirmed by qPCR (Figure 3B). IRAK2 is involved in the
MyD88-dependent response that occurs on dimerization of the
TLR receptor, and is utilized by every TLR except TLR3.
MyD88 recruits IRAK1 and IRAK2, and IRAK kinases
phosphorylate and activate the protein TRAF6, which in turn
polyubiquitinates the protein TGFβ-activated kinase (TAK1) as
well as itself in order to facilitate binding to IKKβ. On binding,
TAK1 phosphorylates IKKβ, which then phosphorylates IκB
causing its degradation and allowing nuclear translocation of
NFκB to activate transcription and consequent induction of
inflammatory cytokines [46].
Stat1/Stat4 and Stat2 expression increased gradually by
12h, and declined somewhat at 24h. In contrast; increase in
Stat3 expression was stable till 24h (Figure 3C). While Socs3
increased rapidly and remained stable, Socs5 expression
declined during LPS stimulation up to 6h and then returned to
the basal level (Figure 3C) confirmed by qPCR in Figure 3D.
LPS-induced changes in STAT/SOCS expression can be
important in the fibrogenic activity of HSCs. For example, IL22-
induced activation of STAT3 and SOCS3 has been implicated
in promoting senescence of HSCs thereby ameliorating fibrosis
[47]. In another study, however, adiponectin-induced SOCS3
activation was found to prevent leptin-mediated fibrogenic
activity of HSCs by inhibiting STAT3 signaling [48]. IFNγ has
been shown to induce quiescence in pancreatic stellate cells
via activation of STAT1 [49]. Clearly, these varied responses of
LPS-induced signaling molecules (IRAK, STAT and SOCS)
indicate instigation of stimulatory and counter-regulatory
pathways in hepatic inflammation and immunity.
The expression of other genes that control cell growth,
proliferation and survival such as Mtor that encodes
mammalian target of rapamycin (mTOR), and related genes
Rptor, Lamtor1, Lamtor2 and Mlst8 were all present in HSCs
and unaffected by LPS stimulation, while Rictor was absent
throughout. Cot/Tpl2 (Map3k8), which controls Akt/mTor/
p70S6k signaling, is increased in LPS-stimulated HSCs (Figure
2A). LPS has also been shown to stimulate the synthesis of
IL10 and IL6 in PBMCs [50], and of TNFα and IL10 in
peritoneal macrophages via mTor activation. However,
inhibition of mTor reduces IL10 and increases TNFα synthesis
[51] indicating mTor signaling is primarily anti-inflammatory. In
this regard, inhibition of mTor augments LPS-induced lung
injury [52] and its stimulation by resveretrol in microglial cells
inhibits inflammatory response by down-regulating NFkB and
MAPK signaling [53]. These data suggest that the interactions
between LPS-induced mTor and other signaling pathways in
HSCs as potential regulators of hepatic inflammation and
immune responses.
LPS-induced cytokine expression
Interleukins, TNF family and nitric oxide.  Microarray
findings showed robust increases in Il6, Il1β, Il1α, Tnfα and
Nos2 (encodes iNOS) in LPS-stimulated HSCs (Figures 4A-C).
The data agree with our previous observation that while the Il6
transcript was still robustly elevated at 24h, the Tnfα transcript
peaked at 3h and decreased thereafter [17]. The validity of the
microarray data was confirmed by increased release of TNFα,
IL6, IL1α and NO metabolites (NO2+NO3) by LPS-stimulated
HSCs (Figure 4D). The LPS-induced increase in TNFα was
also validated by intracellular staining of the cells and
determination via flow (Figure S4). Moreover, changes in each
of these components were accompanied by changes in family
members or in functionally related genes (Figures 4A-C). For
example, Il6, Il1α and Il1β up-regulation was accompanied by a
modest decrease in gene expression of the respective
receptors IL6ra and IL1rl1 (Figure 4A). On the other hand,
gene expression of another receptor for IL1 family of cytokines,
Il1r2, was unchanged. Also, up-regulation of iNOS (Nos2) was
accompanied by >20-fold down-regulation of both heterodimer
components (Gucy1a3 and Gucy1b3) of the soluble guanylate
cyclase, which comprises the intracellular receptor for NO,
presumably to attenuate the autacoid effects of elevated NO on
intracellular signaling (Figure 4C).
Il1α and Il1β transcripts showed early high increase (0-1h),
Il6 increased early (maximum rate at 1-3h), and Il10 showed a
slow, nearly linear increase from 0 to 12h. While culture
activation of HSCs is known to cause an increase in IL10
mRNA, additional stimulation with LPS, TNFα or TGFβ further
increases IL10 mRNA by 2-fold, resulting in greater release of
IL10 protein into the medium [19,54]. Thus the basal as well as
LPS-stimulated HSC-derived IL10 is a significant source of
anti-inflammatory and pro-tolerogenic environment in the liver.
Expression of Il1rn, which encodes the Ilr1 receptor
antagonist, increased >100-fold on LPS treatment. This will
likely inhibit the inflammatory signaling of IL1α and IL1β, and its
downstream effects. LPS also increased gene transcript of a
novel secreted cytokine IL17F by more than 10-fold by 24h
stimulation, but did not affect the other members of IL17 family,
IL17b and IL17d. Although Il17a is not surveyed by the
microarray, IL17A protein was not detected in the culture
supernatants of control or LPS-stimulated HSCs [19,20]. IL17F
bears homology to IL17A, and is expressed and released by
activated CD4+ memory T cells, the CD45-RO+ subset of CD8+
memory T cells and activated monocytes [55]. Recently, IL17
was reported to promote liver fibrosis in mice by activating
inflammatory cells and KCs, and to stimulate collagen
synthesis in HSCs directly through activation of STAT3 [56].
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Since IL17A and IL17F share the same receptors (IL17Ra and
IL17Rc) [55], a similar fibrogenic effect of IL17F via autocrine
pathway in HSCs cannot be ruled out. However, microarray
analysis showed nearly 2-fold (to 52% of control) LPS-induced
decrease in Il17ra expression at 6h, and Il17rc was absent
from all samples; the transcript of another receptor for IL17,
Il17re was also robustly decreased from 6h onwards (not
shown). These data indicate that such down-regulation by LPS
may be a mechanism of limiting fibrogenesis during chronic
liver injury. This effect is also relevant to LPS-induced down-
regulation of the molecules coupled to HSC activation as
shown later (Figures 5 and 9). The other important effects of
IL17F are its potential to inhibit angiogenesis and to stimulate
IL2, TGFβ, and MCP1 synthesis by human endothelial cells,
although it does not stimulate the proliferation of hematopoietic
progenitors or the migration of mature leukocytes [57]. Thus,
expression Il17f by HSCs and its increase by LPS demonstrate
a unique regulatory potential of these cells in hepatic
angiogenesis and inflammatory/immune responses.
Consolidation of data from our previous reports on mouse
HSCs [19,20], the present ELISA (Figure 4D) and microarray
findings (see GEO data) show that rat HSCs do not express
the cytokines typically associated with T cell differentiation/
proliferation (IL2, IL4, IL5, IL13 and IL12p70), without or with
LPS stimulation. Of interest is the observation that isolated KCs
produce IL13, an anti-inflammatory protein [58] and not IL10
under basal conditions [59], and LPS stimulates secretion of
IL10 [43,59] but not of IL13 in these cells [59]. This property of
KCs is quite distinct from the significant spontaneous
production of IL10 by HSCs and its stimulation by LPS (Figure
4) [19].
Among the TNF-related genes, other than Tnfα, Tnfaip6
(encodes TNFα-Induced Protein 6: TNFAIP6) and Tnfrsf5
(encodes type I transmembrane glycoprotein CD40) showed
nearly 100-fold increase by 3h of LPS stimulation that
remained stable for 24h Tnfsf9 (encodes transmembrane
cytokine CD137L) showed a transient increase at 1h after LPS
stimulation, and returned to the basal level by 6h (Figure 4B).
The expression of Tnfaip6 by HSCs and its up-regulation by
LPS suggests a critical regulatory mechanism in liver
pathophysiology considering the involvement of TNFAIP6 in
stabilizing extracellular matrix and cell migration through a
hyaluronan-binding domain, and also in protease network
associated with inflammation by forming a stable complex with
inter-α-inhibitor and enhancing its serine protease inhibitory
activity.
TGFβ and related genes.  LPS induced down-regulation of
Tgfb2 and Tgfb3 in HSCs (Figure 5A). Tgfb1 transcript was
down-regulated by 1.4-fold at 1-3h and up-regulated by 1.5-fold
at 24h. However, qPCR analysis showed decrease in TGFβ1
mRNA at 24h (Figure 5B). In our experience, quiescent and
transitionally activated HSCs are not major sources of TGFβ1.
Interestingly, LPS also strongly down-regulated Tgfbr1
transcript throughout the time-course, and up-regulated the
transcript for TGFβ pseudoreceptor BAMBI (BMP and the
activin membrane bound inhibitor) up to 3h that decreased to
the basal value thereafter (Figures 5A, 5B). These data with
transitionally activated rat HSCs differ from that with quiescent
mouse HSCs in which LPS did not affect Tgfbr1 expression but
down-regulated BAMBI [18]. It was proposed that by down-
regulating BAMBI, LPS enables HSCs to react with
macrophage-derived TGFβ during hepatic fibrogenesis. Our
data, however, suggest that LPS may exert counter-regulatory
actions by up-regulating BAMBI and down-regulating Tgfbr1
expression following the initial period of liver injury when HSCs
are undergoing activation. It is likely that these variable results
may also reflect species-specific effects.
LPS-induced interferon expression and downstream
effects
The microarray surveys Interferons (IFN) α1, β1, γ and κ,
also receptors Ifnar1, Ifngr1 and Ifngr2. Of these, IFNs γ and κ
were undetectable in any sample, while transcripts for Ifnα1
and for receptors were detectable and unchanged. In contrast,
Ifnβ1 showed a very strong transient increase. (see GEO
dataset). To assess the potential autacoid effect of the IFNβ1
transient we assembled a list of known IFN-modulated genes
using the NCBI Gene database, the Interferome.org database,
and supplementary data from Schoggins et al. [60]. From the
Interferome.org database we used only genes which had been
cited in more than one literature report. The aggregate list
contained 372 genes surveyed by the microarray. Of these 207
(55%) were modulated in at least one experiment with
increased expression of 76, 1, and 81 genes respectively in
experiment 1 only, experiment 2 only, and concordantly.
Decreased expression occurred for 21, 6, and 15 genes
respectively, so that increases represent 158 of the total 200
genes (79%). The remaining seven genes were modulated
discordantly. Contingency analysis (χ2 test) showed that twice
as many IFN-responsive genes were modulated as would be
expected by random chance, (-log(p) = 28.8 ) confirming a
robust response to autacoid IFNβ1. We note that five of the ten
Cxcl and five of the ten Ccl family members increased (see
below) are IFN-inducible.
Of nine interferon regulatory factors (Irfs) all are surveyed
except -4 and -8; Irf6 was essentially absent and only -1, -7
and -9 showed robust increases (Figure 6A). IRF1 is reported
to be a major mediator of ischemia/reperfusion injury that
occurs upon partial liver resection and transplantation of the
cold/ischemic preserved graft [61,62]. Expression of IRF1 in
inflammatory cells (e.g., DCs) is coupled to the production of
type 1 IFNs (IFNα and IFNβ); the released type 1 IFNs then
induce IRF1 expression in hepatocytes, which initiates
hepatocyte death via HMGB1 [63]. It is likely that a similar
mechanism of hepatocyte injury may be mediated by LPS-
stimulated HSCs, with IRF1 as an inducer of inflammatory
mediators in HSCs. In contrast, the gene expression of IRF2,
an antagonist of IRF1, did not change in response to LPS,
suggesting that the IRF1 pathway is primarily skewed toward
hepatocyte injury. While the Irf1 transcript decreased
somewhat following initial up-regulation, Irf7 transcript
increased in a stable manner still showing maximal (about 50-
fold) increase at 24h. qPCR results show very weak expression
of IRF7 that increased 150-fold upon LPS stimulation (Figure
6B). IRF7, whose expression has been shown to be restricted
to certain cells types such as B cells and DCs [64], is a key
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innate immune molecule in the type I IFN signaling pathway,
and is essential for the type I IFN response to many viruses
[65]. It is also known that IRF7 forms a complex with MyD88,
which causes activation of IFNα-dependent promoters [66].
IRF9 is a crucial factor for accelerating IFNα-induced early
antiviral signaling [67]. These data show that HSCs instigate a
robust type I IFN response through IRF1- and IRF7-induced
transcriptional activity, with IRF9 optimizing the timing and size
of the response.
Taken together, these data show that LPS stimulates a
transient IFNβ1 response, with subsequent autacoid
modulation of a very substantial population of IFN-sensitive
genes.
LPS effects on CC (cysteine-cysteine) chemokines and
their receptors.  In the CC chemokines, Ccl3 (encodes
MIP1α), Ccl4 (encodes macrophage inflammatory protein-1β:
MIP1β), Ccl5 (encodes RANTES: regulated on activation,
normal T cell expressed and presumably secreted), Ccl6, Ccl7,
Ccl9 (encodes macrophage inflammatory protein-1 gamma:
MIP1γ), Ccl19 and Ccl20 (encodes macrophage inflammatory
protein 3α [MIP3α] or Exodus-1, also known as liver and
activation-regulated chemokine [LARC]) all show >10-fold
increases, while Ccl2 (encodes MCP1) and Ccl22 (encodes
macrophage-derived chemokine [MDC]) show about 4-fold
increases (Figures 7A, 7C). We have previously shown LPS-
induced synthesis of CCL2 and CCL3 [19], and thus the
microarray findings are consistent with LPS-induced ERK1/2
phosphorylation [17,33], which is coupled to up-regulation of
CCL2 and CCL3 [33,68]. The proteins encoded by these
chemokine genes display strong chemotactic activity towards
various inflammatory and immune cells (Table 2). The increase
in CCL2-5 expression in KCs and endothelial cells was
proposed to be an important determinant in a murine model of
fulminant hepatic failure (FHF) and in human FHF patients due
to migration of CD14-positive macrophage and CD3-positive
lymphocytes [69]. Our data suggest that HSCs may also
contribute significantly to this pathology. On the other hand,
CCL2 and CCL3 also induce migration of DCs, and their
subsequent interaction with HSCs renders them tolerogenic
suggesting their protective role in liver allograft transplantation
[20].
Highly activated human (passage 3-9) HSCs were found to
express CCL5 and its receptor CCR5 (70). NFkB-activation by
TNFα, IL1β and CD40L increased CCL5 expression, which
caused migration and proliferation of HSCs [70]. The present
microarray data with transitionally activated rat HSCs also
demonstrate expression of CCL5, which increases upon LPS
stimulation, and is consistent with increased LPS-induced
release of the chemokine in the medium (Figure 7A; inset).
Higher CCL5 gene expression levels were observed in
activated murine HSCs after stimulation with TLR3 ligand poly
I:C as compared to that with LPS [71]. Since CCL5 mRNA
levels are suppressed during early fibrosis by Peg-IFNα in the
HCV infected patients, it was proposed that poly I:C-induced
CCL5 gene expression in HSCs may be involved in regulating
fibrogenesis [71]. Our data showing robust increase in CCR5
expression (about 95-fold by 6h) in LPS-stimulated HSCs
(results not shown) indicate that autocrine CCL5/CCR5
interaction may be a critical event contributing to the liver
damage during acute liver injury and then fibrogenesis. We
note that the chemokines released by LPS-stimulated HSCs
were also shown to play an important role in biliary obstruction-
induced hepatic fibrosis in a mouse model [18].
Among the other receptors of this class, CCR2 (CCL2 and
CCL7), CCR3 (CCL7), CCR4 (CCL7 and CCL22), CCR6
(CCL7, CCL20) and CCR10 (CCL7) were undetectable by
microarray in HSCs without or with LPS stimulation, CCR7
(receptor for CCL19), CCR8 and CCR9 are not addressed by
the microarray, and CCR1 was expressed by HSCs and its
expression increased by 300-fold upon LPS stimulation (results
not shown). The latter results suggest that autocrine effects of
CCL3, CCL6 and CCL9 on HSCs via their receptor CCR1 can
be of potential importance in hepatic pathophysiology.
Interestingly, CCR2, which is mainly expressed by monocytes
and macrophages [72-74], was also reported to be expressed
by mouse HSCs, and based on reduced bile duct ligation- and
CCl4-induced fibrosis in CCR2-/- mice, it was concluded that
CCR2 is responsible for migration of HSCs during liver injury
[72].
LPS effects on CXC (cysteine-X-cysteine) chemokines
and their receptors.  In the CXC chemokines, Cxcl1 (~50-
foldmax), Cxcl2 (~100-foldmax), Cxcl10 (~100-foldmax) and
Cxcl11 (~100-foldmax) increased very rapidly at 1-3h, Cxcl3,
Cxcl5 and Cxcl9 increased with a slight delay with maximal
increase of ~50-100-fold at 3-6h, while Cxcl13 and Cxcl16
increased gradually by about 5-fold by 6h of LPS stimulation
(Figure 7B, 7C). Expression levels of all of these genes
remained stably elevated up to 24h, except that of Cxcl10 that
decreased to ~20-fold by 24h. Cxcl4 and Cxcl12 did not show
Table 2. Chemokines expressed by HSCs and their target
cells.
Chemokine Target cells
CCL2 Monocytes/macrophages, DCs and memory T cells
CCL3 Monocytes, NK cells and memory T cells
CCL4 NK cells, NKT cells, monocytes, Tregs, B cells and DCs
CCL5 Eosinophils, basophils, NK cells and T cells
CCL7 DCs, Monocytes and macrophages
CCL9/CCL10 CD34+ immature myeloid cells and DCs
CCL19 DCs, B cells, memory T cells and Tregs
CCL20 T cells and neutrophils
CCL22 Monocytes, DCs, NK cells, activated T cells and Tregs
CXCL1 Neutrophils, monocytes and T cells
CXCL2 Neutrophils, eosinophils, basophils
CXCL3 Eosinophils, basophils, monocytes, DCs and T cells
CXCL4 Neutrophils, eosinophils, basophils
CXCL5 Neutrophils, eosinophils, basophils
CXCL9 NKT cells, CD4 T cells, CD8 T cells
CXCL10 T cells, neutrophils, monocytes. NK cells
CXCL11 NKT cells, CD4 T cells, CD8 T cells
CXCL13 B cells
CXCL16 NKT cells, CD4 T cells, CD8 T cells
DCs, dendritic cells; NK, natural killer cells; Tregs, regulatory T cells.
doi: 10.1371/journal.pone.0082159.t002
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any appreciable change in response to LPS. The robust and
rapid increase in Cxcl1, Cxcl2, Cxcl4 and Cxcl5 indicate the
strong potential of HSCs in inflammation, angiogenesis (e.g.,
during liver regeneration) and wound healing by causing
chemotaxis of neutrophils, eosinophils and basophils.
Interactions of these pathways with IL17F, which is up-
regulated by LPS (Figure 4A), can be critical in angiogenic role
of HSCs. LPS-induced up-regulation of Ccl2, Cxcl1 and Ccl3 in
HSCs, which suggests their involvement in the recruitment of
monocytes and neutrophils, is supported by our recent
observation showing decreased LPS-induced hepatic
infiltration of neutrophils in HSC-depleted mice [30]. HSCs may
also play a direct role in innate immunity since CXCL1 and
CCL3 (MIP1α) possess anti-bacterial and anti-viral activity,
respectively. Furthermore LPS-induced up-regulation of Cxcl10
(encodes IP10) (Figure 7B) and secretion of IP10 by HSCs
[19,20] provide an additional mechanism of HSC-mediated
recruitment of lymphocytes, neutrophils and monocytes in the
liver.
In addition to Cxcl10, LPS also up-regulated the expression
of Cxcl9 (encodes MIG), Cxcl11 and Cxcl16 indicating that
HSCs can induce migration of NKT cells and conventional CD4
and CD8 T cells. The ability of HSCs to present bacterial lipid
antigens to NKT cells has been shown to be a significant factor
in the control of bacterial infection [24]. Furthermore, HSCs
suppress proliferation and induce apoptosis of conventional T
cells directly as well as by modulating DCs to a tolerogenic
phenotype and by expanding Tregs that acquire superior
immunosuppressive potential [19,20,25]. Our data also shed
light on the possible contribution of HSCs in a murine model of
FHF in which administration of heat-killed Propionibacterium
acnes followed by a low dose of LPS increased the expression
of Ccl5, Cxcl9, Cxcl10, Cxcl16 (the ligand of Bonzo, CXCR6)
and TNFα [75]. Of note is the observation that up-regulation of
Cxcl16 closely correlated with the magnitude of immunological
liver injury induced by BCG-LPS in mice [76], and intrahepatic
recruitment of specific lymphocytes by HSCs might be an
important mechanism of this injury. Moreover, as described
above, LPS-up-regulated Ccl2-5 in HSCs can also contribute to
liver failure.
Among the Cxcr class of receptors, rat HSCs did not express
Cxcr1/Il8ra, Cxcr2/IL8rb and Cxcr5/Blr1, and Cxcr6 is not
surveyed by the microarray. Some differences appear in the rat
and mouse HSCs in regard to the expression of CXCL1 and
CXCR2. While activated but not quiescent mouse HSCs
expressed CXCL1, both phenotypes expressed its receptor
CXCR2 [77]. However, CXCR2 was expressed by the liver
after CCl4-induced injury followed by administration of CXCL1,
leading to a concluded that CXCL1/CXCR2 interaction plays an
important role in liver fibrosis [77]. Interestingly, HSCs express
Cxcr3, Cxcr4 and Cxcr7 transcripts, and LPS modulated the
last two; Cxcr4 is predominantly down-regulated, while
modulation of Cxcr7 is complex (see GEO data). CCR5 and
CXCR4 are the two major co-receptors required for HIV entry
into cells, and the primary HIV isolates were found to infect
both human HSC line, LX-2, and primary human HSCs via
CCR5 and CXCR4, and to promote collagen I expression and
secretion MCP1 [78]. Together, these data provide strong
additional evidence for HSCs to modulate hepatic
microenvironment by attracting and then interacting with
inflammatory and immune cells that have potential implications
in innate and adaptive immunobiology.
Antigen-presenting and co-regulatory
molecules.  Several reports have shown HSC’s ability to
influence T cells by presenting Ag in conjunction with co-
modulatory molecules (e.g., CD80, CD86, B7-H1). For
example, bacterial lipid Ag presentation by HSCs activates
NKT cells and regulates microbial infection [24]. On the other
hand, HSCs induce expansion of Tregs via MHC II [19], cause
apoptosis of T cells via B7H1 (PD-L1) [25], suppress CD8 T
cell activation in a CD54-dependent manner [26], and inhibit
CD8 T cell activation/proliferation via B7H4 [27]. Previously, we
found that LPS induces strong increase in MHC class II and co-
stimulatory molecules CD80 and CD86 as well as VCAM, and
smaller increase in MHC class I, CD40, CD54 and B7H1 in
mouse HSCs [19]. In the present study with rat HSCs, the
B7H1 homolog (CD274/Pdcd1lg1) is not surveyed by the
microarray (see Figure 8A), and Cd80 transcript was
undetectable in any sample. However, Cd86 and Vcam1
transcripts increased in LPS-stimulated HSCs concordantly
with protein expression (Figure 8A). Additionally, the increase
in the transcript for Cd40 was robust, while modest increases
were observed in the transcripts for Icam1 and specific MHC I
molecules. Cd40 and Icam1 transcripts peaked at 6h of LPS
treatment, and by 24h had fallen by 80% and 44% respectively.
This likely explains the previously observed low increases in
the respective encoded proteins in mouse HSCs at 24h of LPS
stimulation [19]. Alternatively, mouse HSCs may respond
differently to LPS as discussed above for TGFβ related
molecules, and chemokines.
Cells of myeloid origin including DCs express receptor for a
glycoprotein OX2 or CD200; CD200R is an inhibitory receptor
that affects myeloid cell functions [79-81]. We have observed
CD200R in liver mDCs and surface expression of CD200 on
HSCs, which is increased by LPS (not shown). These data are
consistent with expression of Cd200 transcript and its 10-foid
increase by LPS within 6h (Figure 8B). We are currently
investigating CD200/CD200R interactions as an important the
mechanism of our prior finding that HSC-modulated DCs are
poor stimulators of T cells [20].
LPS down-regulates activation state of HSCs
Treatment of culture activated rat or human HSCs with
recombinant human IFNβ (rhIFNβ) causes decreased
expression of α-SMA, collagens I and III, TGFβ1, PDGF-BB
and Smad4, while Smad7 expression is increased [82]. The
present data show that LPS causes a robust autacoid IFNβ
response (see above), so we reviewed concurrent cytoskeletal
and fibrotic changes. PDGF-BB is not surveyed by the
microarray, and we found Smad4 expression to be stable but
Smad6 to decrease (see GEO dataset).
Cytoskeletal changes.  A search of the root “cytoskel” in the
NLM Gene database gave 1537 responses, of which 1252 are
surveyed. Of these, 106 showed at least one valid increase
and 218 showed at least one valid decrease. Acta2 encoding
α-SMA, as well as both Acta1 and Actg2 (encoding skeletal
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muscle and smooth enteric muscle actins, respectively) and
Actn1 (nonmuscle α-actinin 1) were robustly decreased.
Nonmuscle myosin II (NMM II) is an actin-binding complex
comprising myosin heavy chains II-A II-B and II-C encoded by
Myh9, Myh10 and Myh14 respectively; regulatory light chains
encoded by Myl12a, Myl12b and Myl9; and essential light
chains such as Myl6 [83]. Myosin heavy chains (Myh) surveyed
are 1, 6, 7, 8, 9, 10, 11, 13, 14, of which only 9, 10, 11 and 14
are detectable. Expression of Myh9 and Myh10 is decreased
as is Myh11, which encodes a smooth muscle chain. Of eight
Myl members surveyed (-1, -2, -3, -4, -6, -7, -9, -12b) -3 and -7
were undetectable and Myl9 was decreased; the remainder
were stably expressed, with Myl6 showing the highest level. Of
three Mylk (myosin light chain kinase) members, the detectable
smooth muscle isoform (Mylk) was decreased by LPS while
Mylk2 and Mylk3 (encoding skeletal and cardiac isoforms
respectively) were undetectable. This confirms the robust
expression of the nonmuscle myosin II complex in HSCs, and a
decrease in four of seven detectable transcripts on stimulation
with LPS. Other structural muscle components, (Figures 9A,
9C), including Cnn1, Cryab, Tagln and Tpm1 (see GEO data)
were also down-regulated >5 fold. Nonstructural genes
associated with muscle development or function including
Dmpk, Dysf, Hspb6, Kcnmb1 and Csf1r were also down-
regulated.
Fibrogenic changes.  Abnormalities in liver function,
including chronic liver diseases, increase circulating LPS
levels. Liver injury is associated with activation of HSCs and
fibrosis suggesting that LPS might be involved in HSC
activation. The present data show that while the mRNA
encoding TGFβ1,TGFβ2 and TGFβ3 are either unaffected or
decreased by LPS, the receptors Tgfbr1 and Tgfbr2 are
decreased, and BAMBI is transiently up-regulated (Figure 5).
Further examination revealed down-regulation of the genes
associated with HSC activation such as Acta 2 (Figure 9A, 9C)
as well as decreased expression of α-SMA, a protein encoded
by this gene in LPS-stimulated transitionally activated rat HSCs
(Figure 9A: inset). In contrast to this effect, LPS up-regulated
Pdgfra transcript by about 10-fold in HSCs (see GEO dataset).
The activation of HSCs is associated with increased expression
of PDGF receptor that is a powerful stimulus for their
proliferation by PDGF produced in the injured liver. Whether
LPS signaling promotes, inhibits or has no effect on PDGF-
induced proliferation of HSCs remains to be determined.
LPS decreased the microarray-assayed expression of
several collagen transcripts by 24h, including Col1a1, Col3a1,
Col4a5, Col5a1 Col8a1, Col12a1 and Col14a1 (Figure 9B).
Col8a2 and Col11a1 showed early transient increases before
decreasing at 24h. On the other hand, fibronectin expression
was high and unchanged (see GEO dataset), while decorin
expression was up-regulated by 10-fold at 24h of LPS
stimulation. Confirmatory qPCR at 24h (Figure 9C) showed a
trend to decrease in Col1a1, stable fibronectin expression, and
increased decorin expression. Decorin has been shown to
regulate collagen fibrillogenesis, to block bioactivity of TGFβ1
and to exert protective effect against fibrosis. Together, these
data indicate that LPS exerts strong anti-fibrogenic effect in the
liver by limiting or down-regulating activation-associated
changes in HSCs. It will be of interest to determine whether
LPS has similar effects on fully activated (passage 3-4) HSCs
and those isolated from chronically injured fibrotic liver (e.g.,
after chronic 12-14 weeks of CCl4 treatment).
HSCs express several matrix metalloproteinases (MMPs)
(the zinc- and calcium-dependent proteases) that degrade
ECM and other extracellular proteins, and their inhibitors
(tissue inhibitors of MMP: TIMPs). These enzymes regulate
ECM components in physiology and an imbalance in their
relative expressions and activities during liver injury is
responsible for ECM remodeling, repair during organ injury and
fibrosis. The microarray data show strong (about 100-fold) up-
regulation of the Mmp3, Mmp9, Mmp10 and Mmp13
transcripts, while Mmp12, -16, -17, -19 and -24 showed no
change (Figure 9D). Timp1 transcript showed 3-fold increase
while Timp2 transcript decreased slowly that was significant at
24h; Timp3 and Timp4 expression levels were not prominent
and did not change over the time-course of LPS stimulation
(see GEO database). Since MMP13 deficiency was shown to
resist liver fibrogenesis due to biliary obstruction [84], and
activated MMP13 converts pro-MMP9 to its active form MMP9,
which induces HSC activation/transdifferentiation [85], these
data suggest that this pathway favors fibrogenesis.
Furthermore, decrease in Timp2 (an inhibitor of MMP13
activation) expression also favors the role for LPS in promoting
fibrogenic activity of HSCs. These data are paradoxical to the
down-regulation of HSC activation markers (Figure 9A) and up-
regulation of MMP3 (degrades collagen types II, III, IV, IX, and
X, proteoglycans, fibronectin, laminin, and elastin), which
indicate that LPS also instigates mechanisms that ameliorate
fibrogenic response of HSCs.
In summary, the functionally validated microarray data
discussed here indicate a crucial role of HSCs in hepatic
inflammation and immune regulation. Limitations on space
preclude full discussion of other facets of the HSC response,
e.g., modulation of growth factor expression (upregulation of
Ngf, Hgf and Vegfa, downregulation of Hbegf, Igf1 and Vegfc),
growth factor receptors (Egfr and Ogfr upregulated; Fgfr3
down-regulated) and up-regulation of the vasoconstrictor
cytokine endothelin-1, all of which will affect the interaction of
HSCs with nonimmune hepatic cells. Obviously, there are
differences in some of the highly important LPS effects on
mouse versus rat HSCs, and it cannot be ruled out that such
differences may likely be observed in the responses of human
HSCs to LPS. It should be considered that while the
experimental rodents are maintained in controlled pathogen-
free environment, humans are subjected to variable
environmental and food-derived factors on a continuous basis,
which can likely alter the responses of HSCs to LPS.
Nevertheless, the present data are of potential importance in
future investigations to discover the varied roles of HSCs in
hepatic inflammation and immunity.
Supporting Information
Figure S1.  Purity of HSCs. (A) Unstimulated or LPS-
stimulated HSCs were harvested using trypsin/EDTA solution,
then stained with anti-CD31 (endothelial cell marker), anti-
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CD68 (Kupffer cell marker), anti-CD11b/c (myeloid cell marker)
or anti-GFAP (HSC marker) Abs and subjected to FACS
analysis on a LSR II Flow Cytometer. Upper panel shows the
purity of HSCs (gated on total live cells), while lower panel
shows the respective isotype controls. (B) Protein lysates of
unstimulated (CT) or LPS-stimulated (LPS) HSCs were
subjected to SDS-PAGE. Separated proteins were transferred
on to PVDF membrane and immunoblotted with anti-CD11b , -
CD31 or -CD68 Abs. After washing, the membranes were
incubated with secondary Ab, and signals were detected using
ECL Western blotting detection reagent (GE Healthcare/
Amersham, Buckinghamshire, UK). Liver lysates were used for
positive control. (C) HSCs on glass coverslips were fixed (with
2% paraformaldehyde), permeabilized and stained for α-SMA
(red) and nuclear stain (DAPI). All the cells are stained positive
for α-SMA and also contained vitamin A (green
autofluorescence).   
(TIF)
Figure S2.  Pairwise comparisons of control vs LPS-
stimulated stellate cells. A contingency analysis of the
agreement between the first and second experiments shows
that genes with ≥3 of 10 valid 2-fold changes in the first
experiment are more than twice as likely than chance would
predict to be modulated in the second experiment. This
concordance is so marked that for ≥ 7 changes in the first
experiment there are ≥ 9-fold more genes with ≥ 3 changes
than expected in the second experiment, and ≥2-fold fewer
genes than expected with zero changes. This is a way of
including concordance between genes which are modulated in
the second experiment (where 1h and 24h are examined) with
genes which respond in the first experiment at intermediate
times (3h, 6h or 12h). Exceptions in the Graph: there is no
enrichment for 5 changes in experiment 1 and 3 changes in
experiment 2; and there are no genes which show 9 changes in
experiment 1 and 2 changes in experiment 2 (gap indicated by
grey doubled-headed arrow).
(TIF)
Figure S3.  Pairwise comparisons of all control vs
stimulated comparisons within each experiment. For
experiment 1 this yields (2 control x 5 stimulated = 10
comparisons), while experiment 2 yields (2 control x 2
stimulated = 4 comparisons), for a total of 14 pairwise
comparisons. The 10,903 unique characterized genes which
shown (14 ≥ n ≥ 0) valid 2-fold differences are shown (unfilled
bars). 1,692 unique characterized genes were found with
values distributed so that p < 0.042 by the Mann-Whitney test.
The numbers of these genes which have corresponding two-
fold changes also are shown (filled bars); the fraction they
represent of those corresponding changes is shown (filled
circles, right hand axis). The progressive increase of this
fraction is consistent with a predominant directionality in the
modulated genes; i.e. most genes are consistently upregulated
or downregulated.
(TIF)
Figure S4.  Intracellular staining of TNFα in stellate cells.
Unstimulated or LPS-stimulated HSCs were harvested using
trypsin/EDTA solution, fixed with 2.0% paraformaldehyde,
permeabilized with 0.1% saponin in PBS containing 0.5% BSA,
then stained with anti-TNFα Ab and subjected to flow
cytometry. Only GFAP+ HSCs were gated to measure TNFα
expression. Black histogram-isotype control; dashed line-
unstimulated HSCs; solid line -LPS-stimulated HSCs.
(TIF)
Table S1.  Primers used in qPCR.
(DOC)
Table S2.  The cells show the number of genes increased,
then the number decreased, by LPS stimulation. There are
1,177 responsive genes exclusive to experiment 1 (shaded
bottom data row), 281 exclusive to experiment 2 (shaded right-
hand data column) and 576 changes concordant between
experiments (dotted box; 345 increases and 252 decreases).
Concordant changes therefore represent 33% and 67% of the
total changes in experiment 1 and experiment 2 respectively.
Of the 1,177 genes exclusive to experiment 1 (i.e.,
nonresponsive at T1 or T24 in experiment 2) a total of 330 had
showed responses at one or more intermediate (3, 6 or 12h)
time-points. Of the 281 genes exclusive to experiment 2, 26
showed one or more responses at the intermediate time points
in experiment 1.
(DOC)
Table S3.  Values are the significance (as -log(p)) of the
enrichment of different pathways in different groups.
Pathways were chosen where at least one group had a value >
3 (i.e., p < 0.001). Values < 1.3 (i.e., p > 0.05) were omitted for
clarity. The enrichment values in this Table and Table C are
calculated by parsing 367 unique genes. This Table contains
pathways for which enrichment of the concordant group is
greater than that of the aggregate group.
(DOC)
Table S4.  Values are the significance (as -log(p)) of the
enrichment of different pathways in different groups.
Pathways were chosen where at least one group had a value >
3 (i.e., p < 0.001). Values < 1.3 (i.e., p > 0.05) were omitted for
clarity. This Table contains pathways for which enrichment of
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